Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGS-8M4 + pegylated liposomal doxorubicin
- Development stage
- Discontinued
- Lead developer
- Astellas Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
AGS-8M4 + pegylated liposomal doxorubicin is a combination therapy intended for the treatment of ovarian cancer, particularly in platinum-resistant or platinum-sensitive settings. **AGS-8M4** is a fully human monoclonal antibody targeting AGS-8, a cell surface antigen highly expressed in advanced ovarian cancers and associated with tumor survival, migration, invasion, and angiogenesis. AGS-8M4 blocks AGS-8 function and inhibits tumor growth and metastasis in preclinical models by direct interference with tumor cell processes, independent of immune effector mechanisms[1][3][5]. **Pegylated liposomal doxorubicin** is a formulation of doxorubicin encapsulated in a pegylated liposome, which preferentially accumulates in tumors via the enhanced permeability and retention effect. It acts as a cytotoxic anthracycline by inhibiting topoisomerase II, blocking DNA replication and leading to cell death[2][4]. The combination was investigated for synergistic anti-tumor activity, with AGS-8M4 targeting a novel cancer antigen and pegylated liposomal doxorubicin delivering chemotherapy[5].
- Other names
- AGS 8M4AGS8M4AGS-8M4pegylated liposomal doxorubicin
02
Targets
GPSM1 (Activator of G-protein signaling 8)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on AGS-8M4 + pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGS-8M4 + pegylated liposomal doxorubicin.